Form 4: Jupiter Neurosciences Director Awarded Stock Options

Jupiter Neurosciences, Inc. reports a grant of stock options to Director Tomas Jan Philipson, with a portion tied to his board appointment and the remainder in lieu of cash compensation.

Summary

• Tomas Jan Philipson, a Director at Jupiter Neurosciences, Inc., was granted 536,428 stock options on June 26, 2026.
• The grant includes 90,000 options for his appointment to the Board of Directors.
• An additional 446,428 options were granted as compensation for annual board retainer and committee fees, replacing cash payments.
• These options have an exercise price of $0.21 and are exercisable starting June 29, 2026, with an expiration date of June 29, 2036.
• The options vest in 12 equal quarterly installments, commencing September 2, 2026, contingent on continued service as a director.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it details standard compensation practices for a director, including an equity grant that aligns incentives, but provides no new operational or financial performance data.

Positives

• Director Tomas Jan Philipson received a significant stock option grant, aligning his interests with the company's performance.
• A portion of the options directly compensates for his role as a Director and committee member, indicating recognition of his contributions.
• The grant structure, with vesting tied to continued service, incentivizes long-term commitment from the director.

Negatives

• The filing does not contain any negative financial or operational information.

Risks

• The value of the stock options is subject to the future performance of Jupiter Neurosciences, Inc.'s stock price.
• Vesting is contingent on continued service, meaning the director could forfeit unvested options if service is terminated.

Future Outlook

The filing primarily details a stock option grant and does not contain forward-looking financial guidance or outlook for the company.

Management Comments

• The grant of options is structured to incentivize continued service and align director interests with shareholder value.
• A portion of the compensation for board retainer and committee fees is being delivered via equity rather than cash.

Industry Context

StockSavvy.ai notes that granting stock options to directors is a common practice in the biotechnology and pharmaceutical sectors, like Jupiter Neurosciences, Inc., to attract and retain talent and align executive and director incentives with long-term shareholder value creation.

Corporate Governance

Related Party Transactions

• Grant of 536,428 stock options to Director Tomas Jan Philipson, with 90,000 for his board appointment and 446,428 in lieu of cash compensation for retainer and committee fees.

Stakeholder Impact

• Shareholders: The stock option grant dilutes ownership slightly but aligns director incentives with long-term company performance.
• Employees: This filing does not directly impact employees, but reflects the company's compensation philosophy.
• Management: The filing confirms compensation arrangements for a key director.

Next Steps

• Tomas Jan Philipson will continue to serve as a Director of Jupiter Neurosciences, Inc.
• The stock options will vest quarterly starting September 2, 2026, subject to continued service.
• The company will continue to operate under its 2025 Equity Incentive Plan.

Key Dates

Keywords

stock options, director compensation, Jupiter Neurosciences, equity incentive plan, board appointment, beneficial ownership, SEC Form 4